Bone Abstracts

ADO2 is a debilitating genetic bone disease causing multiple fractures and other severe symptoms. A mouse model of ADO2, harbouring the heterozygous Clcn7G213R gene mutation, phenocopies the human syndrome. The Clc7 gene encodes the ClC7 dimeric 2Cl−/1H+ antiporter that is almost ubiquitously expressed, although the mutations hit especially the osteoclasts impairing bone resorption. By immunofluorescence, we observed that the mutant ClC7 ...

Estrogens are important regulators of bone mass and exert their physiological effects on bone mainly via estrogen receptor α (ERα). Central ERα has been reported to exert an inhibitory role on bone mass. ERα is widely distributed in the brain with a high expression in the arcuate nucleus (ARC) and the ventral medial nucleus (VMN) in the hypothalamus. Here, we tested the hypothesis that ERα in hypothalamic pro-opiomelanocortin (POMC) neurons, located in...

Duchenne muscular dystrophy (DMD) is associated with osteoporosis, and dystrophic (dystrophin-deficient) mdx mice show reduced bone mass characterised by decreased mineral apposition and elevated bone resorption. To investigate a potential role of the G-protein-coupled receptor protease-activated receptor-2 (PAR2) in the muscle and bone pathology associated with DMD, we established a colony of PAR2-null-mdx mice. Limb and diaphragm muscles, tibiae and ser...

Maternal vitamin D status has been positively associated with infant bone mass in observational studies. We therefore evaluated whether 1000 IU/day cholecalciferol during pregnancy would lead to greater offspring bone mass at birth, in a UK, multicentre, randomised, double-blind, placebo-controlled trial (MAVIDOS, ISRCTN82927713).At 12 weeks’ gestation, pregnant women with a serum 25-hydroxyvitamin D [25(OH)D] 25-100 nmol/l were randomised to either...

STRUCTURE was a phase 3, open-label study evaluating the effect of romosozumab or TPTD for 12 months in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy (NCT01796301). This study enrolled women with postmenopausal osteoporosis who had taken an oral bisphosphonate for ≥3 years prior to screening and alendronate in the year prior to screening; had a BMD T-score ≤−2.5 at the total hip (TH), lumbar spine (LS), or femoral neck (FN);...

In XLH, high circulating FGF23 causes hypophosphatemia, rickets, and short stature. In our Phase 2 study, 52 XLH children (ages 5-12 years, ≥Tanner 2) were randomized to receive KRN23 subcutaneously biweekly (Q2W) or monthly (Q4W). Serum phosphate (Pi) was measured biweekly. KRN23 dose was titrated (maximum 2 mg/kg) targeting age-appropriate serum Pi concentrations.The first 36 subjects had a mean 6.6 years of standard-of-care treatment before wash...